Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00462761 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00462761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00462761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2007
Completion date
December 31, 2009
Enrollment
76 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, aml, leukemia, mds, myelodysplastic syndrome